Source: International Congress 2018 – Innovative therapies in asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Chanez (Marseille, France), Y. Adir (Haifa, Israel), M. Castro (St Louis, United States of America), L. Pahus (Marseille, France), M. Mcdonald (Malvern, United States of America), L. Hickey (Malvern, United States of America), M. Garin (Malvern, United States of America). Intravenous (IV) reslizumab improves asthma control, symptoms, and quality of life in patients with historically elevated blood eosinophils. 600

Member's Comments

No comment yet.

Related content which might interest you: Clinical characteristics, lung function, quality of life, exercise capacity and inflammatory biomarkers in induced sputum and serum in children and adolescents with uncontrolled severe asthma. Source: International Congress 2019 – Severe acute asthma and troublesome wheezing Year: 2019 Omalizumab significantly improves quality of life in patients with severe persistent allergic asthma: a pooled analysis Source: Eur Respir J 2005; 26: Suppl. 49, 49s Year: 2005 A treatment algorithm adjusting oral corticosteroid using blood eosinophils reduces exacerbations and improves asthma control, in difficult asthmatics Source: International Congress 2016 – Systemic biomarkers Year: 2016 Influence of tiotropium bromide (TB) on the severity of clinical, functional symptoms and health-related quality of life (HRQL) in COPD patients (pts) Source: Annual Congress 2011 - COPD management Year: 2011 Effects of low dose inhaled theophylline (ADC4022) co-administered with budesonide on inflammatory markers, lung function, and quality of life in COPD patients Source: Annual Congress 2009 - New drugs for airways disease Year: 2009 Improvement of control and quality of life in severe allergic asthmatics patients treated with omalizumab Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008 Relationship between sputum inflammatory parameters, symptom scores and reduced quality of life in asthmatic patients Source: Eur Respir J 2003; 22: Suppl. 45, 179s Year: 2003 Relationship between severity of bronchial and systemic inflammation, and dyspnea, exercise performance and quality of life in patients with stable COPD Source: Eur Respir J 2006; 28: Suppl. 50, 37s Year: 2006 Reslizumab (RES) in patients (pts) with inadequately controlled asthma and elevated blood eosinophils (EOS): Analysis of two phase 3, placebo-controlled trials Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives Year: 2016 Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Dysfunctional breathing in patients with severe asthma is associated with poor asthma control and low quality of life. Source: International Congress 2017 – Techniques to treat asthma Year: 2017 Are health related quality of life (HRQoL) changes maintained after several years treatment with nasal vontinuous positive airway pressure (nCPAP)? Source: Eur Respir J 2003; 22: Suppl. 45, 94s Year: 2003 One year monitoring of children with bronchial asthma and other allergic diseases treated with inhaled corticosteroids vs cromoglycates with serum ECP (S-ECP), FEV1, total IgE and blood eosinophil count - the influence of different therapy Source: Eur Respir J 2002; 20: Suppl. 38, 432s Year: 2002 Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms & morning activities in COPD patients Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 Dual bronchodilation with once-daily QVA149 improves dyspnea and health status and reduces symptoms and rescue medication use in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Intravenous (IV) reslizumab efficacy does not differ by blood eosinophil lowering to levels above or below 50 cells/µL Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018 Ensifentrine added on to tiotropium significantly improves lung function, symptoms and QoL in symptomatic COPD patients regardless of baseline reversibility Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020 QAW039 (fevipiprant) improves lung function and control of asthma symptoms in patients with more severe air flow limitation: A proof-of-concept study Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 The level of health-related quality of life (HRQL) in patients with moderate to severe COPD and its relationship to symptoms Source: Eur Respir J 2002; 20: Suppl. 38, 249s Year: 2002 Effect of BMI on asthma control, asthma severity and quality of life in adult patients with asthma Source: Annual Congress 2011 - Asthma: improving diagnosis and management for reaching better control Year: 2011